Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00505245 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

New Assessment System in Measuring Symptom Distress in Cancer Patients

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. 6 versions Re-verified since May 6, 2024, no change to tracked fieldsv45-v50
  2. Primary completion date: Apr 30, 2030 to Apr 30, 2031v44
  3. Site contact updatedv43
  4. Primary completion date: Apr 30, 2020 to Apr 30, 2030 Completion date: Apr 30, 2020 to Apr 30, 2031v42 Show 1 more changeShow less
    • Completion date: Apr 30, 2020 to Apr 30, 2031
  5. 2 versions Re-verified since Feb 11, 2020, no change to tracked fieldsv40-v41
Show 38 earlier versionsHide 38 earlier versions
  1. Primary endpoints: 5 to 8 Enrollment target: 5500 to 6500v39 Show 1 more changeShow less
    • Enrollment target: 5500 to 6500

    See this version in full on ClinicalTrials.gov ↗

  2. Primary endpoints: 1 to 5 Enrollment target: 5000 to 5500 · Primary completion date: Apr 2020 to Apr 30, 2020 · Completion date: Apr 2021 to Apr 30, 2020 · 8 morev38 Show 11 more changesShow less
    • Enrollment target: 5000 to 5500
    • Primary completion date: Apr 2020 to Apr 30, 2020
    • Completion date: Apr 2021 to Apr 30, 2020
    • Start date: Apr 1999 to Apr 13, 1999
    • Interventions: Survey (Behavioral) to Interview (Other), Quality-of-Life Assessment (Other), Questionnaire Administration (Other)
    • Study description shortened, about 160 words
    • Study site revised
    • Collaborators: 6 to 7
    • Study title revised
    • Eligibility criteria shortened, about 1 word
    • Secondary endpoints shortened, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  3. Collaborators: 4 to 6v37 See this version in full on ClinicalTrials.gov ↗
  4. Completion date: Apr 2020 to Apr 2021 Eligibility criteria expanded, about 4 wordsv36 Show 1 more changeShow less
    • Eligibility criteria expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  5. Enrollment target: 4500 to 5000 Study description shortened, about 35 wordsv35 Show 1 more changeShow less
    • Study description shortened, about 35 words

    See this version in full on ClinicalTrials.gov ↗

  6. Primary and study completion dates: Apr 2019 to Apr 2020v34
  7. Collaborators: 3 to 4v33 See this version in full on ClinicalTrials.gov ↗
  8. Primary completion date: Apr 2018 to Apr 2019 Completion date: Apr 2019v32 Show 1 more changeShow less
    • Completion date: Apr 2019
  9. 3 versions Re-verified since Jun 23, 2016, no change to tracked fieldsv29-v31
  10. Primary completion date: Apr 2017 to Apr 2018v28
  11. Enrollment target: 3500 to 4500 Study description revisedv27 Show 1 more changeShow less
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  12. Study description expanded, about 1 wordv26 See this version in full on ClinicalTrials.gov ↗
  13. Primary completion date: Apr 2016 to Apr 2017 Study description shortened, about 22 words · Eligibility criteria expanded, about 1 wordv25 Show 2 more changesShow less
    • Study description shortened, about 22 words
    • Eligibility criteria expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  14. Enrollment target: 2500 to 3500 Eligibility criteria expanded, about 110 words · Study description shortened, about 3 wordsv24 Show 2 more changesShow less
    • Eligibility criteria expanded, about 110 words
    • Study description shortened, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  15. Collaborators: 2 to 3v23 See this version in full on ClinicalTrials.gov ↗
  16. Enrollment target: 2450 to 2500 Eligibility criteria shortened, about 6 words · Collaborators expanded, about 4 wordsv22 Show 2 more changesShow less
    • Eligibility criteria shortened, about 6 words
    • Collaborators expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  17. Study description expanded, about 13 words Study site revisedv21 Show 1 more changeShow less
    • Study site revised

    See this version in full on ClinicalTrials.gov ↗

  18. Primary completion date: Apr 2015 to Apr 2016v20
  19. 2 versions Re-verified since Nov 14, 2013, no change to tracked fieldsv18-v19
  20. Primary completion date: Apr 2014 to Apr 2015 Study description expanded, about 161 wordsv17 Show 1 more changeShow less
    • Study description expanded, about 161 words

    See this version in full on ClinicalTrials.gov ↗

  21. Re-verified, no change to tracked fieldsv16
  22. Enrollment target: 1950 to 2450 Study description revisedv15 Show 1 more changeShow less
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  23. Re-verified, no change to tracked fieldsv14
  24. Primary completion date: Apr 2012 to Apr 2014v13
  25. Eligibility criteria expanded, about 4 words Study description expanded, about 2 wordsv12 Show 1 more changeShow less
    • Study description expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  26. Study description revisedv11 See this version in full on ClinicalTrials.gov ↗
  27. Re-verified, no change to tracked fieldsv10
  28. Primary completion date: Apr 2011 to Apr 2012v9
  29. Study site revisedv8 See this version in full on ClinicalTrials.gov ↗
  30. Primary completion date: Apr 2009 to Apr 2011v7
  31. Primary endpoint revised Secondary endpoints: 2 to 1v6 Show 1 more changeShow less
    • Secondary endpoints: 2 to 1

    See this version in full on ClinicalTrials.gov ↗

  32. Study title expanded, about 4 wordsv5 See this version in full on ClinicalTrials.gov ↗
  33. Study description revisedv4 See this version in full on ClinicalTrials.gov ↗
  34. Primary endpoint revisedv3 See this version in full on ClinicalTrials.gov ↗
  35. Primary completion date: Apr 2009 Interventions: M.D. Anderson Inventory (MDASI) (Behavioral) to Survey (Behavioral) · Eligibility criteria revised · Study arms: 0 to 1v2 Show 3 more changesShow less
    • Interventions: M.D. Anderson Inventory (MDASI) (Behavioral) to Survey (Behavioral)
    • Eligibility criteria revised
    • Study arms: 0 to 1

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial studies how well a new assessment system (MDASI or other MD Anderson-developed PRO instrument) works in measuring symptoms and the impact on quality of life in cancer patients. Development of a new assessment system may provide more information about the common symptoms that may occur in patients due to cancer and its treatment and how the symptoms impact quality of life.
Trial Details
NCT Number NCT00505245
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI), Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, National Institutes of Health (NIH)
Conditions Caregiver, Health Care Provider, Malignant Neoplasm, Physician
Enrollment 6,500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov